These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer]. Tsukamoto S; Akaza H Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140 [TBL] [Abstract][Full Text] [Related]
7. Update of hormonal treatment in cancer of the prostate. Alivizatos G; Oosterhof GO Anticancer Drugs; 1993 Jun; 4(3):301-9. PubMed ID: 8358057 [TBL] [Abstract][Full Text] [Related]
8. Hormonal therapy of prostatic carcinoma. Defining the challenge. Crawford ED Cancer; 1990 Sep; 66(5 Suppl):1035-8. PubMed ID: 2203516 [TBL] [Abstract][Full Text] [Related]
10. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]. Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258 [TBL] [Abstract][Full Text] [Related]
11. Hormonal therapy of prostate cancer: current concepts and future prospects. Smith JA Clin Ther; 1988; 10(3):281-6. PubMed ID: 3078908 [TBL] [Abstract][Full Text] [Related]
14. Endocrine therapy: where do we stand and where are we going? Schröder FH Cancer Surv; 1991; 11():177-94. PubMed ID: 1841751 [TBL] [Abstract][Full Text] [Related]
15. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475 [TBL] [Abstract][Full Text] [Related]
16. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; Van der Kwast T; Wiegel T; Zattoni F; Heidenreich A Eur Urol; 2011 Apr; 59(4):572-83. PubMed ID: 21315502 [TBL] [Abstract][Full Text] [Related]
17. Endocrine treatment of prostate cancer: standard treatment and new perspectives. Boccardo F; Pace M In Vivo; 1993; 7(5):423-4. PubMed ID: 8110985 [TBL] [Abstract][Full Text] [Related]
18. [Hormonal therapy (medical orchiectomy) in prostatic carcinoma]. Studer UE; Münch D Schweiz Med Wochenschr; 1990 Jun; 120(24):881-7. PubMed ID: 2193381 [TBL] [Abstract][Full Text] [Related]
19. [The combined radiation and hormonal therapy of prostatic carcinoma: a conceptual analysis]. Sommerkamp H; Slanina J Strahlenther Onkol; 1991 Sep; 167(9):523-9. PubMed ID: 1718045 [TBL] [Abstract][Full Text] [Related]
20. Hormone treatments in the common 'hormone-dependent' carcinomas. Wood BC Palliat Med; 1993; 7(4):257-72. PubMed ID: 7505186 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]